Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

Slides:

Advertisements

Similar presentations

Treatment of Vasculitis: immunesuppressives and biologics

Advertisements

Where Are We on the Path to Elimination of Chronic Hepatitis C?

The Nurse View: Management of Pancreatic Cancer

nAMD: Choosing the Best Treatment for your Patient

Improving Survival in Glioblastoma Multiforme

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pneumocystis prophylaxis in ANCA vasculitis

Optimizing Use of Biological Agents in Ulcerative Colitis

The Nurse View.

Ask the Onychomycosis Expert, Part 2

Ask the Onychomycosis Expert, Part 1

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Beyond the Basics: What You Need to Know About Treating Insomnia

Current and Future Goals in the Treatment of Relapsed CLL

Treating Transplant-Ineligible Patients With Multiple Myeloma

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

A Closer Look at Pemphigus Vulgaris: Clinical Challenges and Emerging Treatments.

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Team-Based Perspectives on Successful Approaches in Treating Obesity

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Is it Time for a Paradigm Change in HIV Management?

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Individualizing Factor Replacement Therapy for Patients With Hemophilia.

New Agents, New Regimens, New Strategies

Evaluating Next-Generation BTK Inhibitors

EHL Technologies in Hemophilia Care

Gene Therapy: Past, Present, and Future

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Personalized Therapy in Relapsed or Refractory CLL

Advancing the Treatment of IBD With Biologics

Management of Systematic Lupus Erythematosus

The Evolving Treatment Landscape in Atopic Dermatitis

Key Questions for nAMD Treatment Success

Staying Abreast of Best Practices Across the Clinical Continuum

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Parkinson Disease Psychosis

Program Goals Overview Is NEDA a Reasonable Target?

When to Start and What to Use

nAMD: Choosing the Best Treatment for your Patient

Cancer-Associated Thrombosis

Implications of Emerging Treatments for Beta-Thalassemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

A Guideline-Based Approach to HCV Care

The Changing Field of Melanoma: Ipilimumab.

Are We Making Progress in the Management of Huntington Disease?

Optimizing Joint Health in Hemophilia

Communicating With Your Patients About Major Depressive Disorder

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

From Adjuvant to Metastatic in Melanoma

Clinical Challenges and Updates in Managing Seizure Clusters

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Program Goal. Program Goal Disclaimer Overview.

Program Goals Overview Is NEDA a Reasonable Target?

AMD Therapy: Where Are We Now and Where Are We Going?

At the Crossroads of Coagulation

Clinical Challenges in the Patient With Relapsed Multiple Myeloma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of Nontuberculous Mycobacterial Lung Disease.

Exploring the Use of Adeno-Associated Virus for Gene Therapy

Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.

Current standard of care treatment protocols for LN induction therapy.

Presentation transcript:

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis

Vasculitis Overview

Patient, KB Initial Presentation

Work Up

Signs of Severe Disease: GPA

Induction Regimen Selection

Choosing Between CYC and RTX Favors RTX

RTX + CYC

RTX Dosing

CYC Dosing and Safety

Plasma Exchange in AAV

Plasma Exchange in KB

KB Follow-Up 1 Month

Monitoring the AAV Patient

KB Follow-up, Laboratory Results

Treating KB

KB Follow-up, 4 Months

Further Prednisone Taper

Considerations for Adding Another Agent

Maintenance Therapies

Maintenance Therapies (cont.)

KB Follow-up, 9 Months

Change KB’s Treatment Regimen?

KB Follow-up, 12 Months

Treating Relapse Considerations

Abbreviations